Companies in #Hypertension

Autonomix Medical (NASDAQ: AMIX) is a development-stage medical device company headquartered in The Woodlands, Texas, advancing a catheter-based precision neuromodulation platform for sensing and treating disorders of the nervous system. The company's microchip-enabled sensing architecture is designed to detect low-amplitude neural signals from within the vascular system, with an initial focus on treating pancreatic cancer pain and expansion into chronic pain management, hypertension, and cardiovascular indications. On August 4, 2026 the company announced a broad new U.S. patent (No. 12,433,670) supporting nerve sensing, mapping, and targeted therapy, following a July 24, 2026 preclinical study demonstrating renal nerve sensing and neural activity change. The stock surged 434% on the August 4 announcement before giving back 24.6% in after-hours trading.

CVRx is a commercial-stage medical device company commercializing Barostim, an implantable neuromodulation device that delivers electrical pulses to carotid baroreceptors to restore baroreflex activation therapy for patients with cardiovascular disease, primarily heart failure. Incorporated in 2000, headquartered in Minneapolis, and listed on Nasdaq in June 2021, the company sells through a direct sales force in the US and Germany. Its August 2026 Q2 report showed $15.7 million in revenue with 87% gross margins but a sharp cut to the full-year 2026 revenue outlook, triggering a roughly 60% single-day repricing and downgrades from Lake Street and Craig-Hallum.

Clinical-stage biopharmaceutical company developing tissue-targeted PDE5 inhibitor RTN-001 for uncontrolled and resistant hypertension and other serious cardiovascular conditions.

French health technology company that designs and manufactures connected health devices including smart scales, blood pressure monitors, thermometers, and the new StethO Sense for heart and lung sound analysis.